Teva Pharmaceuticals is urging a federal judge in Delaware to reject GlaxoSmithKline’s motion to enhance a $235 million infringement award concerning a “skinny label” version of GSK’s cardiovascular drug, Coreg. Teva argues that judicial opinions at various court levels indicate the case lacks clear-cut resolution. This ongoing legal battle underscores the contentious nature of pharmaceutical patent disputes, particularly involving skinny labeling, where partial indications are removed from a generic drug’s label to sidestep patent infringement claims.
For more detailed information on the case, please refer to the full article on Law360.